The DUSP23 Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-mediated gene-disrupted polyclonal knockout cell population engineered to ablate expression of the dual-specificity phosphatase DUSP23 in the near-haploid human HAP1 cell line. This polyclonal knockout pool provides a genetically heterogeneous loss-of-function model suitable for studying DUSP23-dependent cellular processes without clonal selection biases. The CRISPR/Cas9 editing strategy introduces target-gene disruption, generating a functional knockout population that allows robust interrogation of DUSP23’s role in signal transduction and cancer biology.
The HAP1 cell line is a near-haploid human fibroblast-like adherent cell line originally derived from a male patient with chronic myeloid leukemia. Its near-haploid karyotype simplifies genetic manipulation and enables high-efficiency CRISPR-based functional genomics screens, making it a well-established model for gene-knockout studies. HAP1 cells retain key signaling pathways, including the MAPK/ERK cascade, and exhibit rapid growth, facilitating large-scale phenotypic assays. The chronic myeloid leukemia origin further provides a disease-relevant context for investigating phosphatase-mediated tumor suppression and oncogenic signaling.
DUSP23 is a dual-specificity protein phosphatase that selectively dephosphorylates the mitogen-activated protein kinases ERK1 and ERK2, serving as a critical negative regulator of MAPK/ERK signaling. Under physiological conditions, DUSP23 expression is induced by growth factor stimulation through ERK1/2-dependent transcriptional feedback, attenuating signal amplitude and duration. The enzyme directly interacts with phospho-ERK1/2 substrates, and its activity modulates downstream effectors including the transcription factors ELK1 and c-FOS. DUSP23 operates within a canonical signaling module comprising growth factor receptors, RAS, RAF, MEK1/2, and ERK1/2, and its loss disrupts this feedback control, leading to sustained ERK activation.
In the HAP1 near-haploid background, disruption of DUSP23 creates a potent model for examining the consequences of unchecked MAPK pathway activity. The loss of DUSP23-mediated dephosphorylation is expected to result in hyperphosphorylation of ERK1/2, driving enhanced cell proliferation and dysregulated cell cycle progression. Additionally, DUSP23 has been implicated in centrosome duplication control, and its knockout may lead to centrosome amplification, providing insights into chromosome instability in cancer. The polyclonal nature of the population ensures representation of multiple knockout clones, averaging out clonal artifacts and allowing assessment of global gene-loss phenotypes. This system is particularly valuable for dissecting negative feedback mechanisms and identifying synthetic lethal interactions in leukemia-derived cells.
These DUSP23 knockout HAP1 polyclonal cells are ideally suited for a range of research applications including quantitative analysis of MAPK signaling dynamics via phospho-ERK1/2 Western blotting, cell proliferation and viability assays, flow cytometric cell cycle profiling, and centrosome duplication studies using immunofluorescence microscopy. The cells also serve as a platform for RNA-seq-based transcriptomic profiling to uncover DUSP23-dependent gene expression programs and for phospho-signaling pathway analysis to map altered kinase networks. Their utility extends to drug discovery efforts targeting MAPK-driven cancers and investigations into resistance mechanisms against MEK or ERK inhibitors. For further technical details, please contact Ascent Research.
